Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM6B | O15054 | 1/20 | 0.59 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 15/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7674711 | 1.00 | KDM6B (0.59) | KDM6BADRA2AADRA2BADRA2CADRA1A | |
| SCHEMBL7242198 | 0.83 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL5317203 | 0.78 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL8632112 | 0.77 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL30841998 | 0.75 | ADRA2A (0.62) | ADRA2AADRA2BADRA2CADRA1AADRB3 | |
| SCHEMBL7670233 | 0.75 | ADRB3 (0.72) | ADRB3ADRB2ADRB1 | |
| SCHEMBL7670238 | 0.75 | ADRB3 (0.72) | ADRB3ADRB2ADRB1 | |
| SCHEMBL5691448 | 0.75 | KDM6B (1.00) | KDM6BADRA2BADRA1A | |
| SCHEMBL18469325 | 0.75 | KDM6B (1.00) | KDM6BADRA2BADRA1A | |
| SCHEMBL29350434 | 0.75 | KDM6B (1.00) | KDM6BADRA2BADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436914-B1 | TREATING DIABETES, OBESITY, DEPRESSION, ACHALASIA OR INTESTINAL HYPERMOTILITY DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-20 | — | — | US | disclosed |
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | SHER PHILIP M (US) | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020026065-A1 | 2-hydroxy-3 - (4-hydroxy-3-sulfonamidophenyl) - propylamines useful as beta 3 adrenergic agonists | ADRB3, ADRB1, ADRA1A | KDM6B 3593/4885ADRA2A 5/4885ADRA2B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.